BMS-986525, OPDIVO 10 mg/mL concentrate for solution for infusion.
CA258-0001
Phase 2 small_molecule active
Quick answer
BMS-986525, OPDIVO 10 mg/mL concentrate for solution for infusion. for Relapsed/Refractory Small Cell Lung Cancer is a Phase 2 program (small_molecule) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bristol-Myers Squibb / Pfizer EEIG
- Indication
- Relapsed/Refractory Small Cell Lung Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active